Case Report

Lipid Lowering Inefficacy of High-dose Statin Therapy Due to Concurrent Use of Phenytoin

Authors: Hasnain M. Khandwala, MD, FRCPC

Abstract

HMG-CoA reductase inhibitors (“statins”) are the most commonly prescribed lipid lowering agents. Most of the statins are metabolized by the CYP450 cytochrome system. A number of medications either induce or inhibit this system which leads to changes in the bioavailability of the statins and the potential for either an increase in adverse effects or reduction in efficacy. Phenytoin induces the CYP3A4 isoform of the CYP450 system and can reduce the bioavailability, and thus the efficacy of the statins metabolized by this enzyme, including atorvastatin and lovastatin. A case of a patient on multiple lipid-lowering medications, including high-dose atorvastatin whose LDL cholesterol improved significantly after discontinuation of phenytoin is presented, and a review of the literature for similar cases is discussed.


Key Points


* HMG-CoA reductase inhibitors (“statins”) are the most commonly prescribed lipid-lowering agents and most of them (atorvastatin, cerivastatin, lovastatin, simvastatin) are metabolized by the CYP3A4 isoform of the CYP450 cytochrome system.


* Phenytoin induces the CYP450 system and can reduce the bioavailability and thus the efficacy of statins.


* Physicians should be aware of the interaction between statins and phenytoin and consider either discontinuing the antiseizure medication if possible, or instituting agents which do not induce the CYP450 system.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Wiviott SD, de Lemos JA, Cannon CP, et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 2006;113:1406–1414.
 
2. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol 2005;96:54F–60F.
 
3. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343–370.
 
4. Piacentini N, Trifiro G, Tari M, et al. Statin-macrolide interaction risk: a population-based study throughout a general practice database. Eur J Clin Pharmacol 2005;61:615–620.
 
5. Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002;41:1195–1211.
 
6. Maxa JL, Melton LB, Ogu CC, et al. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann Pharmacother 2002;36:820–823.
 
7. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109(23 Suppl I):III-50–III-57.
 
8. Silva MA, Swanson AC, Gandhi PJ, et al. Statin-related adverse events: a meta-analysis. Clin Ther2006;28:26–35.
 
9. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42:1141–1160.
 
10. Muck W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000;39:99–116.
 
11. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003;4:495–505.
 
12. Murphy MJ, Dominiczak MH. Efficacy of statin therapy: possible effect of phenytoin. Postgrad Med J 1999;75:359–360.
 
13. Lee LS, Nafziger AN, Bertino JS Jr. Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Clin Pharmacol Ther 2005;78:1–6.